Provista Blog > Cancer Moonshot: Advancing Early Detection
The Cancer Moonshot 2020 initiative is led by Vice President Joe Biden. The objective of the program is to make more therapies available to more patients, while also improving the ability to prevent cancer and detect it at an early stage. The primary goal of Cancer Moonshot is to make a decade’s worth of cancer research progress in five years and to bring the most promising science and clinical developments to cancer patients in the near future.
It is well known that early detection and intervention of breast cancer improves the probability of patient survival. To improve the current landscape of early detection, the project aims to become more knowledgeable about how biomarkers are associated with cancer development. This, in turn, aims to accelerate development, testing and broader adoption of proven strategies to reduce the risk and relative impact of cancer. The initiative is also focused on reducing unnecessary deaths in the general population, populations that experience persistent cancer disparities and populations with familial cancer risk such as Hereditary Breast and Ovarian Cancer (HBOC).
The program combines the resources of multinational pharmaceutical, biotechnology companies, academic centers and community oncologists. Through this, Cancer Moonshot 2020 has aspirations to change how we treat and detect cancer, with the ultimate outcome of preventing death as a result of the disease.
The Cancer MoonShot 2020 Program is one of the most comprehensive cancer collaborative initiatives launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational moonshot to develop an effective vaccine-based immunotherapy to combat cancer by 2020.
To read more about the Cancer Moonshot 2020 Program, read the Blue Ribbon Panel report.
At Provista Diagnostics, our mission is to develop world-class diagnostic tests for indications in breast and gynecologic cancers. As a leading diagnostics company, our aim is to create, produce and market innovative solutions for unmet clinical needs. Our products and services help to diagnose diseases and inform better clinical decisions, thus enhancing women’s health and quality of life. We do this in a responsible and ethical manner with a commitment to excellence in every aspect of our business.